SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001829126-23-007422
Filing Date
2023-11-14
Accepted
2023-11-14 16:15:42
Documents
53
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q titanpharma_10q.htm   iXBRL 10-Q 625859
2 EXHIBIT 10.4 titanpharma_ex10-4.htm EX-10.4 146335
3 EXHIBIT 31.1 titanpharma_ex31-1.htm EX-31.1 15179
4 EXHIBIT 32.1 titanpharma_ex32-1.htm EX-32.1 7421
  Complete submission text file 0001829126-23-007422.txt   3728511

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ttnp-20230930.xsd EX-101.SCH 30819
6 XBRL CALCULATION FILE ttnp-20230930_cal.xml EX-101.CAL 43800
7 XBRL DEFINITION FILE ttnp-20230930_def.xml EX-101.DEF 106746
8 XBRL LABEL FILE ttnp-20230930_lab.xml EX-101.LAB 255817
9 XBRL PRESENTATION FILE ttnp-20230930_pre.xml EX-101.PRE 200594
47 EXTRACTED XBRL INSTANCE DOCUMENT titanpharma_10q_htm.xml XML 464026
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

IRS No.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-13341 | Film No.: 231406469
SIC: 2836 Biological Products, (No Diagnostic Substances)